Curaleaf Holdings (CURLF) Other Accumulated Expenses (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Other Accumulated Expenses of $5.6 million for Q4 2025, up 761.35% year-on-year from $652000.0 in Q4 2024, and up 761.35% on a QoQ basis from $652000.0 in Q4 2024.
Curaleaf Holdings (CURLF) Other Accumulated Expenses (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Other Accumulated Expenses for 7 consecutive years, with $5.6 million the latest figure, recorded in Q4 2025.
- Quarterly Other Accumulated Expenses rose 761.35% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.6 million (up 761.35% YoY) and the FY2025 annual result came in at $5.6 million, up 761.35% from the prior year.
- Other Accumulated Expenses climbed to $5.6 million in Q4 2025 per CURLF's latest filing, from $652000.0 in the prior quarter.
- Over the last five years, Other Accumulated Expenses for CURLF reached as high as $12.2 billion in Q1 2022 and fell as low as $359000.0 in Q3 2023.
- A 5-year average of $822.9 million and a median of $3.4 million in 2024 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 840959.15% — and 2023, when it plunged 98.81%.
- Year by year, Other Accumulated Expenses stood at $12.2 million in 2021, then plunged by 85.84% to $1.7 million in 2022, then declined by 27.1% to $1.3 million in 2023, then slumped by 48.09% to $652000.0 in 2024, then soared by 761.35% to $5.6 million in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $5.6 million, $652000.0, and $3.4 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Curaleaf Holdings | 6.95 Bn | 6.95 Bn | 157.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.62 Mn |
| Dec 31, 2024 | 652,000.00 |
| Sep 30, 2024 | 3.36 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Dec 31, 2023 | 1.26 Mn |
| Sep 30, 2023 | 359,000.00 |
| Jun 30, 2023 | 1.20 Mn |
| Dec 31, 2022 | 1.72 Mn |
| Sep 30, 2022 | 30.17 Mn |
| Jun 30, 2022 | 28.86 Mn |
| Mar 31, 2022 | 12.23 Bn |
| Dec 31, 2021 | 12.17 Mn |
| Sep 30, 2021 | 12.57 Mn |
| Jun 30, 2021 | 13.08 Mn |
| Mar 31, 2021 | 1.45 Mn |
| Dec 31, 2020 | 6.57 Mn |
| Sep 30, 2020 | 6.81 Mn |
| Dec 31, 2019 | 31.55 Mn |